ABSTRACT
RACIONAL: Os tumores neuroendócrinos (TNEs) são raros e compreendem apenas 0,49% de todas as neoplasias malignas. A maioria acomete o trato gastrointestinal. OBJETIVO: Analisar os fatores demográficos, características clinicopatológicas, tratamento empregado, fatores prognósticos e resultados oncológicos relacionados aos TNEs colorretais. MÉTODOS: No período compreendido entre 1996 e 2010 foram tratados 174 pacientes. Destes, 34 localizavam-se no cólon e reto. Foram analisados fatores demográficos, estadiamento, os procedimentos terapêuticos aplicados e seus resultados. No seguimento todos os pacientes foram acompanhados acima de três anos com exames de imagem, dosagem de 5-HIIA urinário, cromogranina-A sérica e fosfatase ácida prostática. RESULTADOS: A média de idade no diagnóstico foi de 54,5 anos (22-76), com predominância do sexo feminino (64,7%). Dos 12 com TNEs de cólon, um (8,3%) foi classificado como estádio IA; um (8,3%) em IB; três (25%) em IIIB e sete (58,4%) em IV. Dos 22 pacientes com TNEs de reto, seis (27,3%) foram classificados como estádio IA; quatro (18,2%) em IB; três (13,6%) em IIIA; um (4,5%) em IIIB e oito (36,4%) em IV. Dos TNEs de reto, nove (41%) foram tratados com ressecção endoscópica, seis (27,2%) com procedimento cirúrgico e seis (27,2%) somente com quimioterapia. Onze pacientes com TNEs de cólon (91,6%), foram tratados cirurgicamente, sendo sete paliativamente, um (8,4%) com ressecção endoscópica e nenhum foi submetido à quimioterapia no primeiro momento. Após seguimento médio de 55 meses, 19 (55%) pacientes estavam vivos. Analisando a sobrevida global obteve-se média de 29 meses no estádio IA, 62 meses no IB, 12 meses no IIIA, 31 meses no IIIB e 39 meses no IV. CONCLUSÃO: O tratamento dos TNEs de cólon e reto é complexo, pois depende de variáveis que são individuais a cada paciente. Com adequado manuseio, o prognóstico pode ser favorável e a sobrevida longa, mas ela está relacionada ao grau de diferenciação tumoral, tamanho, localização do tumor, estadiamento no momento do diagnóstico, eficácia da terapêutica adotada e à aderência do paciente ao seguimento após o tratamento.
BACKGROUND: Neuroendocrine tumors (NETs) are rare, comprising nearly 0.49% of all malignancies. The majority occurs in the gastrointestinal tract. AIM: To analyze the demographic factors, clinicopathologic features, treatment employed, prognostic factors and the oncologic results related to colorectal NETs. METHODS: Between the period from 1996 to 2010 174 patients were treated. From these, 34 were localized in the colon and rectum. Demographic factors, stage, therapeutics and its results were analyzed. All patients were followed for more than three years with image exams, urinary 5-hydroxyindolacetic acid (5-HIIA), serum chromogranin A and prostatic acid phosphatase. RESULTS: The median age was 54,4 years (22-76), the majority was female (64,7%). Out of the 12 patients with colon NETs, one (8.3%) patient was classified as Stage IA; one (8.3%) as Stage IB; three (25%) as Stage IIIB and seven (58.4%) as Stage IV. Out of the 22 patients with rectum NETs, six (27.3%) were classified as Stage IA; four (18.2%) as IB; three (13.6 %) as IIIA; one (4.5%) as IIIB and eight (36.4%) as IV. Of rectal NETs, nine (41%) were treated with endoscopic resection, six (27.2%) underwent conventional surgical treatment and six (27.2%) were treated with chemotherapy. Eleven patients with colon NETs (91.6%) were surgically treated, seven of them with palliative surgery, one (8.4%) was treated with endoscopic resection and no patient was submitted to chemotherapy. After an average follow-up of 55 months, 19 (55%) patients were alive. Analyzing the overall survival was obtained an average overall survival of 29 months in Stage IA, 62 months in IB, 12 months in IIIA, 31 months in IIIB and 39 months in IV. CONCLUSION: The treatment of colon and rectal NETs is complex, because it depends of the individuality of each patient. With adequate management, the prognosis can be favorable with long survival, but it is related to the tumor differentiation degree, efficacy of the chosen treatment and to the patient adhesion to the follow-up after treatment.